Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) saw its stock touch a 52-week low of $518.68 as the biotech firm contends with heightened market volatility and shifting investor sentiment. The stock ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet ...

View the latest Regeneron Pharmaceuticals Inc. (REGN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Over the past five years, Regeneron Pharmaceuticals' total shareholder return reached 46.55%, showcasing its resilience amidst a challenging market. This period witnessed several pivotal developments.

Data & APIs. Events. Premarket ...

Regeneron Pharmaceuticals's REGN short percent of float has fallen 3.19% since its last report. The company recently reported that it has 2.80 million shares sold short , which is 2.73% of all ...

Regeneron Pharmaceuticals’ Debt total was $2.7 Billion at the conclusion of the most recent quarter, while its market capitalization is $52 Billion (as of 5/30/2025).

Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow. Apr. 06, 2025 2:36 AM ET Regeneron Pharmaceuticals, Inc. (REGN) Stock SNY, REGN 35 Comments 1 Like. Stephen Ayers.

Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on Regeneron (REGN – Research Report). The associated price target was lowered to $1,183.00. Terence Flynn has given his ...